Leniolisib is a medication approved for the treatment of activated PI3K-delta syndrome (APDS) in patients two years of age and older [1]. APDS is a rare, primary immunodeficiency that affects the immune system's ability to regulate itself [1][2]. Leniolisib is an oral selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) enzyme [1].
How does leniolisib work?
Leniolisib targets the PI3Kδ pathway, which is overactive in individuals with APDS [1][2]. This enzyme plays a crucial role in the function of certain immune cells, and its dysregulation leads to the characteristic symptoms of APDS, including frequent infections, autoimmune complications, and lymphoproliferation [1][2]. By inhibiting PI3Kδ, leniolisib helps to restore normal immune cell function and reduce the severity of APDS manifestations [1].
What conditions can leniolisib treat?
Currently, leniolisib is approved to treat activated PI3K-delta syndrome (APDS) [1]. APDS is a genetic disorder where the PI3Kδ pathway is constitutively active. This hyperactivity impacts various immune cell types, leading to a range of clinical problems [1][2].
When was leniolisib approved?
Leniolisib received approval from the U.S. Food and Drug Administration (FDA) on March 24, 2023 [1].
What are the potential side effects of leniolisib?
Common side effects reported during clinical trials for leniolisib include edema (swelling), upper respiratory tract infections, headache, and diarrhea [1]. Serious adverse reactions observed in some patients have involved infections and hypersensitivity reactions [1].
How is leniolisib administered?
Leniolisib is an oral medication, meaning it is taken by mouth [1]. The dosage is typically administered twice daily [1].
What is the typical dosage of leniolisib?
The recommended dosage for leniolisib is 50 mg taken orally twice daily [1].
What are the safety considerations for leniolisib?
Patients taking leniolisib should be monitored for signs of infection and hypersensitivity reactions [1]. The medication should be used with caution in individuals with a history of these conditions [1]. It is essential to discuss any pre-existing medical conditions and current medications with a healthcare provider before starting leniolisib [1].
Are there any drug interactions with leniolisib?
Leniolisib is metabolized by cytochrome P450 3A4 (CYP3A4) [1]. Therefore, concurrent use with strong CYP3A4 inhibitors may increase leniolisib exposure, and use with strong CYP3A4 inducers may decrease leniolisib exposure [1]. Patients should inform their doctor about all medications they are taking to avoid potential interactions [1].
What is the source of information on leniolisib?
Information on leniolisib, including its approval status, mechanism of action, indications, dosage, and safety profile, is available from regulatory bodies and pharmaceutical information resources [1]. Specific details on drug patents and exclusivity can be found on platforms such as DrugPatentWatch.com [3].
When does leniolisib's patent expire?
The patent expiry for leniolisib is a critical factor for potential generic or biosimilar competition [3]. Specific patent expiration dates are detailed in patent filings and can be tracked through patent databases [3]. These dates determine the period of market exclusivity for the innovator drug [3].
Who manufactures leniolisib?
Leniolisib is manufactured by Pharming Healthcare, Inc. [1].
---
Sources
[1] https://www.janssen.com/news/pharmaceutical-company-janssen-announces-us-fda-approval-phil-veon-lenilidib-tablets-treatment-activated-pi3kdelta-syndrome-APDS
[2] https://www.mayoclinic.org/diseases-conditions/primary-immunodeficiency/about/contents/ptl-20047827
[3] https://drugpatentwatch.com/